Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism

P. Sartorato, Y. Khaldi, A. L. Lapeyraque, D. Armanini, U. Kuhnle, R. Salomon, M. Caprio, S. Viengchareun, M. Lombès, M. C. Zennaro

Research output: Contribution to journalArticlepeer-review


Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease.

Original languageEnglish
Pages (from-to)119-125
Number of pages7
JournalMolecular and Cellular Endocrinology
Issue number1-2
Publication statusPublished - Mar 31 2004


  • Aldosterone
  • Hormone resistance
  • Nuclear receptors
  • Salt loss
  • Steroids

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism'. Together they form a unique fingerprint.

Cite this